By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tobira Therapeutics Inc. 

214 Carnegie Center
Suite 306
Princeton  New Jersey  08540  U.S.A.
Phone: 609-897-1102 Fax: n/a


Company News
Tobira Therapeutics Inc. Highlights Data Presentations At The American Association for Study of Liver Diseases Annual Meeting Supporting Its Phase 2b Program Of Cenicriviroc For Nonalcoholic Steatohepatitis 11/10/2014 9:11:09 AM
Tobira Therapeutics Inc. Doses First Patient In CENTAUR, A Phase 2b Study Of Cenicriviroc In Patients With Non-Alcoholic Steatohepatitis 10/13/2014 7:39:29 AM
Tobira Therapeutics Inc.' Cenicriviroc Shows Improvement In Liver Fibrosis Scores In Phase 2b Study To Be Presented At AASLD 10/1/2014 8:53:13 AM
Bay Area Biotech Firm Tobira Therapeutics Inc. Tables $74 Million IPO 8/7/2014 3:15:50 PM
South San Francisco's Tobira Therapeutics Inc. Wraps Up $15 Million Loan Agreement 7/1/2014 7:05:52 AM
Tobira Therapeutics Inc. Adds To Its Board Of Directors 6/23/2014 8:15:16 AM
Tobira Therapeutics Inc. Appoints Chairman Laurent Fischer, MD, Chief Executive Officer And Christopher Peetz Chief Financial Officer 3/26/2014 1:20:31 PM
Tobira Therapeutics Inc. Presents Data Supporting Anti-Fibrotic Activity of Cenicriviroc in Liver Disease Models at The Liver Meeting 2013 11/4/2013 6:43:07 AM
Tobira Therapeutics Inc. Presents Positive 48-Week Data From Phase 2b Trial of Cenicriviroc in Treatment-Naïve HIV Infection at the 14th European AIDS Conference 10/17/2013 7:08:04 AM
Tobira Therapeutics Inc. Announces Publication of Cenicriviroc Formulation Improvement Providing Platform for Single Tablet and Fixed-Dose Combinations 10/4/2013 9:54:09 AM